Latest Clinical Trials News

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Neurizon Therapeutics has boosted the participant count in its HEALEY ALS Platform Trial Regimen I from 160 to 240, capitalising on faster enrolment and philanthropic support to maintain costs and accelerate topline results to early Q3 2027.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.

Aroa Biosurgery posted a breakout FY26, beating revenue and EBITDA guidance with a 54% surge in Myriad sales. The company plans significant investments in FY27 to accelerate growth and capitalise on new market opportunities.

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.